Eli Lilly and Company (LLY)
Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market
Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition to the home country of its biggest weight-loss rival, Danish pharmaceuticals group Novo Nordisk.
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lilly's Alzheimer's drug approved in the UK
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the company said on Wednesday.
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
Fewer contenders means fewer constraints on expanding market share.
Lilly sues online vendors, medical spa over copycat weight-loss drugs
Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets.
Eli Lilly Buy On Weakness Signal (Technical Analysis)
Eli Lilly has triggered multiple Buy signals, including Timing, SAR, and Fundamental, with a 12-month target of ~$1,150. Technical indicators like Full Stochastic, Chaikin money flow, and ADX Demand signal show bullish trends and outperformance versus the Index. Despite strong Growth, Momentum, and Profitability scores, poor Valuation and Revision scores make LLY risky, leading to potential selling on good news.
1 Reason to Buy Eli Lilly Stock Hand Over Fist Right Now
Eli Lilly just secured a huge win, and it's not related to the weight loss industry.
Lilly Loses Around $14B This Week: How to Play LLY Stock
Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.
2 High-Flying Growth Stocks With Massive Upside Potential
These innovative drugmakers have potential catalysts ahead.
This is Huge News For Eli Lilly Investors
Eli Lilly is investing billions into new research and manufacturing capabilities.
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
This Artificial Intelligence Move Is One New Reason to Buy Eli Lilly Stock in 2024
Lilly is staying ahead of the technology curve instead of falling behind.
